ICD code T39.8X5S – Nonopioid analgesic adverse effect sequela

Key takeaways

T39.8X5S is a 7-character billable ICD-10-CM code; the 6-character parent T39.8X5 is not billable.

The S suffix marks a sequela encounter, where the reaction has resolved and left a lasting complication.

T39.8 is a residual group: aspirin, other salicylates, acetaminophen, pyrazolones, NSAIDs and antirheumatics each have their own T39 code.

Sequence the code for the lasting condition first and T39.8X5S second, and never report T39.8X5S alone.

Pabau, the practice management platform we build, validates each claim before it goes to your clearinghouse.

ICD-10 Code T39.8X5S: Quick reference summary

ICD-10 Code T39.8X5S is the billable code for a lasting condition left by a resolved reaction to a nonopioid analgesic or antipyretic. It covers drugs with no more specific T39 code. The drug was taken as prescribed, and the original reaction is over.

The code is valid for FY 2027 (October 1, 2026 through September 30, 2027). Verify current validity each fiscal year via the CDC/NCHS ICD-10-CM web tool.

What does T39.8X5S mean? Breaking down the code structure

T39.8X5S is a seven-character code where each position carries a specific clinical assertion. Reading it position by position shows where sequela suffix errors start.

The X placeholder in position five is purely structural and holds the 7th-character slot open. Submitting T39.8X5 without the final S creates a non-billable header code, a frequent source of claim edits.

T39.8X5A vs T39.8X5D vs T39.8X5S: Choosing the right 7th character

The 7th character records the encounter type. All three codes share the same drug category and adverse-effect classification; only the encounter type differs.

The decision rule is short. If the adverse reaction is still active and being treated, use the A or D code. If it has resolved but left behind a residual condition, use the S code. These encounter types are mutually exclusive, so never assign A or D and S together for the same drug event.

Adverse effect vs poisoning vs underdosing: Why the distinction matters

Adverse effect, poisoning, and underdosing are three different clinical scenarios, and ICD-10-CM codes them through different 6th-character values. Selecting the wrong one changes the intent classification of the encounter and creates a payer mismatch.

The adverse effect classification (6th character 5) requires the provider to document that the drug was taken correctly as prescribed. If documentation is silent on this or describes a dosing error, the correct classification is poisoning, not adverse effect. Per the CMS ICD-10-CM coding guidelines, Section I.C.19.e governs this distinction for Chapter 19 codes.

What is a sequela encounter and when is T39.8X5S applicable?

A sequela is a condition that is the direct result of a previous injury or illness. Here, it is the lasting complication of a prior adverse drug reaction. T39.8X5S applies when the original adverse reaction has resolved but left behind a residual condition the patient is now being managed for.

The residual condition can be renal, gastrointestinal, hepatic or another lasting change the provider ties to the earlier reaction. The clinical test is simple. If the drug-related adverse reaction itself is still active, S is wrong, so use A or D.

• Sequela scenario: Patient was treated 18 months ago for an adverse reaction to prescribed nefopam, a nonopioid analgesic the Table of Drugs indexes to T39.8. They now present with chronic kidney impairment attributed to that prior event. Use T39.8X5S with the chronic kidney disease code sequenced first.
• Not a sequela scenario: Patient is currently experiencing GI bleeding from an ongoing adverse reaction to a prescribed T39.8 analgesic. Use T39.8X5A (initial) or T39.8X5D (subsequent) depending on the encounter stage.
• Timing is not the sole determinant: The passage of time alone does not convert an encounter to a sequela. The provider must explicitly link the current condition to a resolved prior adverse event.

Which drugs T39.8X5S covers

T39.8X5S covers nonopioid analgesics and antipyretics that ICD-10-CM does not classify elsewhere in T39. The Table of Drugs and Chemicals decides which drugs land here, and nefopam is one it indexes to T39.8. The AAPC ICD-10-CM code reference shows the same subcategory structure.

Most common nonopioid pain relievers route to a named subcategory instead, each with its own sequela code:

• Aspirin: T39.015S
• Other salicylates: T39.095S
• Acetaminophen and other 4-aminophenol derivatives: T39.1X5S
• Pyrazolone derivatives, such as metamizole: T39.2X5S
• Propionic acid derivatives, such as ibuprofen and naproxen: T39.315S
• Other NSAIDs: T39.395S
• Antirheumatics not elsewhere classified: T39.4X5S

The diagram below runs the three checks in order: the drug, the intent, then the state of the reaction.

Verify the specific drug in the Table of Drugs and Chemicals before assigning T39.8X5S. This is a residual NEC category, so a more specific T39 subcategory always takes precedence. The ICD List reference tool offers a quick lookup of drug-to-code mappings within the T39 family.

Documentation requirements for T39.8X5S

Sequela encounters require more documentation than initial or subsequent encounters. The provider must establish a causal link between a past event and a current condition.

Missing any of the four documentation elements below converts T39.8X5S into an unsupportable code. Good medical billing compliance starts with provider notes that contain these elements at the time of dictation.

1. Identify the specific drug: The note must name the drug or drug class that caused the original adverse reaction. “Analgesic” alone is insufficient, because the entry must be specific enough to locate in the Table of Drugs under T39.8.
2. Confirm correct-as-prescribed use: The provider must state or clearly imply the drug was taken as directed. Without this, the encounter cannot be classified as an adverse effect, and the coder must query the provider.
3. Link the sequela to the prior adverse event: The note must tie the current condition, such as stage 3 CKD, to the prior reaction. “History of analgesic nephropathy” paired with the current CKD diagnosis satisfies this; “chronic kidney disease” in isolation does not.
4. Describe the sequela manifestation: The clinical description of the current condition must appear in the note. It becomes the manifestation code sequenced ahead of T39.8X5S.

Example documentation language

“Patient presents with stage 3 chronic kidney disease, assessed as a sequela of a prior adverse reaction to [drug name]. The drug was prescribed at the correct dose and discontinued after the adverse event 14 months ago. The CKD is directly attributable to the prior adverse drug reaction.”

Code sequencing rules for T39.8X5S

For adverse effect encounters, ICD-10-CM Section I.C.19.e requires the manifestation code (the condition caused by the adverse effect) to be sequenced before T39.8X5S. This sequencing rule applies to the sequela encounter as well, per Section I.B.10.

1. Sequence the sequela manifestation code first, for example N18.30 (chronic kidney disease, stage 3 unspecified) or K29.70 (gastritis without bleeding).
2. Sequence T39.8X5S second. It identifies the cause of the manifestation and the encounter type.
3. External cause code: T36–T50 codes already include the intent, so no separate external cause code is needed for the drug event. Individual payer policies still vary, so confirm with your specific payer.

Never submit T39.8X5S as the sole diagnosis code. Without the preceding manifestation code, the claim names no condition being treated, and payers deny it.

Common coding errors and claim denial reasons for T39.8X5S

T39.8X5S denials usually trace back to one of five errors, and each one can be caught before submission. Effective denial management workflows build these checks into the billing routine.

Payer and billing guidance for T39.8X5S

Medicare and Medicaid accept T39.8X5S as a valid sequela encounter code when correctly paired with a manifestation and supported by documentation. Sending the claim through a clearinghouse such as the Claim.MD clearinghouse runs it past payer-specific edits before adjudication.

Commercial payer policies vary, so confirm one point before submission. Some payers ask for an external cause code alongside the sequela encounter even though the T39 code already carries the intent. Check the individual payer’s policy or claims submission guide.

• Medicare: Accepts sequela encounter coding per ICD-10-CM guidelines, provided the manifestation code is sequenced correctly.
• Medicaid: State programs follow the national ICD-10-CM code set, and state Medicaid policies may add requirements.
• Commercial payers: Policies on external cause codes vary, so verify per payer before final code assignment.
• HIPAA 837P / 837I: T39.8X5S travels in the diagnosis loop of the electronic claim, with the manifestation code in the primary position.

Practices that run error-checking claims management software can review the T39.8X5S and manifestation code pairing before submission. A grounding in medical billing fundamentals also cuts rework when payer edits flag missing sequencing data.

Includes, excludes, and related codes

T39.8X5S sits within the T39.8 subcategory (other nonopioid analgesics and antipyretics, not elsewhere classified). The NEC qualifier is the main scope check. Confirm the drug does not belong to a named T39 subcategory before you use the residual code.

For the current code hierarchy, inclusions, and exclusion notes, the CDC/NCHS ICD-10-CM web tool carries the authoritative annual tabular list. Neighboring adverse-effect codes for other drug classes follow the same A, D and S pattern in our free diagnostic code library.

How Pabau keeps T39.8X5S claims clean before submission

A sequela claim often passes through three hands. The provider documents the reaction, a coder picks the T39 code, and someone rekeys both into a clearinghouse portal. Each handoff can drop the manifestation code or the S.

In Pabau’s claims software, the claim opens pre-filled from the invoice, and the patient’s insurer and policy details already sit on the client card. Claim validation flags missing or invalid details before you submit. US claims go out as CMS-1500s through Claim.MD.

If a payer still rejects the claim, Pabau shows the reason so you can correct it and resubmit. Payments settle from electronic remittance advice files, and insurance claiming is included in every subscription.

Catch claim errors before the payer does

Pabau pre-fills each claim from the invoice and validates it before submission, so missing or invalid details get fixed first.

Book a demo

Conclusion

Before you assign T39.8X5S, confirm three facts in the note. The drug has no named T39 subcategory, it was taken as prescribed, and the original reaction has resolved. If any one of them fails, a neighboring code fits better.

The trade-off is a few extra lines of documentation at the visit against rework after a denial. A note that names the drug and ties the lasting condition to it will hold up on audit. Book a demo to see how Pabau validates each claim from the invoice before it reaches your clearinghouse.

Continue your research

Need to understand denial patterns before they cost you? Medical claim denial management covers the full workflow for identifying, appealing, and preventing the most common payer rejections.

Coding another drug’s adverse effect sequela? ICD-10 code T45.3X5S applies the same S logic to an adverse effect of enzymes.

Want fewer claims bounced back for rework? What is a clean claim? lists the details a claim needs to pass payer edits on the first submission.

Frequently asked questions